Clinical Trial

Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC

Recruiting
View on ClinicalTrials.gov →
Summary
A unique combinational treatment for cancer employing intratumoral diffusing alpha radiation emitter device with check point inhibitor for recurrent unresectable or metastatic Head and Neck Squamous Cell Carcinoma
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-09-14; most recent amendment 2026-03-31.
Status change: Not Yet Recruiting → Recruiting 2021-10-20
Trial Details
NCT Number NCT05047094
Lead Sponsor Alpha Tau Medical LTD.
Conditions Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma
Enrollment 48 participants
Start Date 2021-11-02
Primary Completion 2026-12 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-06